SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: ghmm who wrote (353)3/16/2011 9:35:16 AM
From: rkrw  Respond to of 507
 
They don't need to wait until full P2 data to begin.

Interesting on the 125 patient expansion, that's not trivial.



To: ghmm who wrote (353)3/16/2011 11:44:21 AM
From: idos  Read Replies (1) | Respond to of 507
 
They did say that phase III will start in 1H '12 so not waiting for full phase II data. Has Robin said if patients in the expanded trial are Doxil pre-treated and get the q21d regimen? If so, I think they want more data on the better responders and regimen to take forward to phase III.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News